Microenvironmental Interactions in Chronic Lymphocytic Leukemia: The Master Role of CD49d

Seminars in Hematology

Volumn 51, Issue 3, 2014, Pages 168-176

  Dal Bo, Michele ^a   Tissino, Erika ^a   Benedetti, Dania ^a   Caldana, Chiara ^a   Bomben, Riccardo ^a   Del Poeta, Giovanni ^b   Gaidano, Gianluca ^c   Rossi, Francesca Maria ^a   Zucchetto, Antonella ^a   Gattei, Valter ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE INHIBITOR; CD38 ANTIGEN;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CANCER SURVIVAL; CELL CLONING; CELL EXPANSION; CELL INTERACTION; CELL POPULATION; CELL PROTECTION; CELL STRUCTURE; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; EXTRACELLULAR MATRIX; GENETIC ASSOCIATION; GENETIC DISORDER; HUMAN; LEUKEMIA CELL; LYMPHOID ORGAN; MALIGNANT TRANSFORMATION; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRISOMY 12; TUMOR MICROENVIRONMENT;

ANTIGENS, CD38; B-LYMPHOCYTES; HUMANS; INTEGRIN ALPHA4; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; SIGNAL TRANSDUCTION; TRISOMY; TUMOR MICROENVIRONMENT;

EID: 84904429269     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2014.05.002     Document Type: Article

References (95)

1. Chiorazzi N., Rai K.R., Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005, 352:804-815.
2. Calin G.A., Dumitru C.D., Shimizu M., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002, 99:15524-15529.
3. Klein U., Lia M., Crespo M., et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010, 17:28-40.
4. Chiorazzi N., Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 2003, 21:841-894.
5. Chiorazzi N., Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood 2011, 117:1781-1791.
6. Bulian P., Shanafelt T.D., Fegan C., et al. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol 2014, 32:897-904.
7. Damle R.N., Wasil T., Fais F., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94:1840-1847.
8. Dohner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910-1916.
9. Gattei V., Bulian P., Del Principe M.I., et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 2008, 111:865-873.
10. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., Stevenson F.K., Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848-1854.
11. Rossi D., Cerri M., Deambrogi C., et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009, 15:995-1004.
12. Zenz T., Eichhorst B., Busch R., et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010, 28:4473-4479.
13. Dal B.o.M., Bomben R., Zucchetto A., et al. Microenvironmental interactions in chronic lymphocytic leukemia: hints for pathogenesis and identification of targets for rational therapy. Curr Pharm Des 2012, 18:3323-3334.
14. Herishanu Y., Perez-Galan P., Liu D., et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011, 117:563-574.
15. O'Brien S., Furman R.R., Coutre S.E., et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014, 15:48-58.
16. Friedberg J.W., Sharman J., Sweetenham J., et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115:2578-2585.
17. Hoellenriegel J., Meadows S.A., Sivina M., et al. The phosphoinositide 3[U+05F3]-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011, 118:3603-3612.
18. Hartmann T.N., Grabovsky V., Wang W., et al. Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrow. Cancer Res 2009, 69:3121-3130.
19. Panayiotidis P., Jones D., Ganeshaguru K., Foroni L., Hoffbrand A.V. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1996, 92:97-103.
20. Lagneaux L., Delforge A., Bron D., De Bruyn C., Stryckmans P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998, 91:2387-2396.
21. Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol 2003, 123:380-388.
22. Ghia P., Circosta P., Scielzo C., et al. Differential effects on CLL cell survival exerted by different microenvironmental elements. Curr Top Microbiol Immunol 2005, 294:135-145.
23. Burger J.A., Ghia P., Rosenwald A., Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009, 114:3367-3375.
24. de la Fuente M.T., Casanova B., Moyano J.V., et al. Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J Leukoc Biol 2002, 71:495-502.
25. Rose D.M., Han J., Ginsberg M.H. Alpha4 integrins and the immune response. Immunol Rev 2002, 186:118-124.
26. Ruoslahti E. Integrins. J Clin Invest 1991, 87:1-5.
27. Danussi C., Petrucco A., Wassermann B., et al. EMILIN1-alpha4/alpha9 integrin interaction inhibits dermal fibroblast and keratinocyte proliferation. J Cell Biol 2011, 195:131-145.
28. Danussi C., Del Bel B.L., Pivetta E., et al. EMILIN1/alpha9beta1 integrin interaction is crucial in lymphatic valve formation and maintenance. Mol Cell Biol 2013, 33:4381-4394.
29. Till K.J., Lin K., Zuzel M., Cawley J.C. The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood 2002, 99:2977-2984.
30. Till K.J., Spiller D.G., Harris R.J., Chen H., Zuzel M., CLL Cawley JC. but not normal, B cells are dependent on autocrine VEGF and alpha4beta1 integrin for chemokine-induced motility on and through endothelium. Blood 2005, 105:4813-4819.
31. Redondo-Munoz J., Ugarte-Berzal E., Terol M.J., et al. Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain. Cancer Cell 2010, 17:160-172.
32. Bauvois B., Dumont J., Mathiot C., Kolb J.P. Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons. Leukemia 2002, 16:791-798.
33. Kamiguti A.S., Lee E.S., Till K.J., et al. The role of matrix metalloproteinase 9 in the pathogenesis of chronic lymphocytic leukaemia. Br J Haematol 2004, 125:128-140.
34. Redondo-Munoz J., Escobar-Diaz E., Samaniego R., Terol M.J., Garcia-Marco J.A., Garcia-Pardo A. MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 2006, 108:3143-3151.
35. Redondo-Munoz J., Ugarte-Berzal E., Garcia-Marco J.A., et al. Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood 2008, 112:169-178.
36. Majid A., Lin T.T., Best G., et al. CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. Leuk Res 2011, 35:750-756.
37. Hidalgo A., Sanz-Rodriguez F., Rodriguez-Fernandez J.L., et al. Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-dependent adhesion to fibronectin and VCAM-1 on bone marrow hematopoietic progenitor cells. Exp Hematol 2001, 29:345-355.
38. Sanz-Rodriguez F., Hidalgo A., Teixido J. Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 2001, 97:346-351.
39. Zucchetto A., Benedetti D., Tripodo C., et al. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res 2009, 69:4001-4009.
40. Menten P., Wuyts A., Van D.J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 2002, 13:455-481.
41. Burger J.A., Quiroga M.P., Hartmann E., et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009, 113:3050-3058.
42. Murphy P.M., Baggiolini M., Charo I.F., et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000, 52:145-176.
43. Kaufmann A., Salentin R., Gemsa D., Sprenger H. Increase of CCR1 and CCR5 expression and enhanced functional response to MIP-1 alpha during differentiation of human monocytes to macrophages. J Leukoc Biol 2001, 69:248-252.
44. Guarini A., Chiaretti S., Tavolaro S., et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood 2008, 112:782-792.
45. Burger J.A., Tsukada N., Burger M., Zvaifler N.J., Dell'Aquila M., Kipps T.J. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000, 96:2655-2663.
46. Tsukada N., Burger J.A., Zvaifler N.J., Kipps T.J. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood 2002, 99:1030-1037.
47. Ghia P., Strola G., Granziero L., et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol 2002, 32:1403-1413.
48. Kitada S., Zapata J.M., Andreeff M., Reed JC Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999, 106:995-1004.
49. Buggins A.G., Levi A., Gohil S., et al. Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. Br J Haematol 2011, 154:216-222.
50. Deaglio S., Vaisitti T., Billington R., et al. CD38/CD19: a lipid raft-dependent signaling complex in human B cells. Blood 2007, 109:5390-5398.
51. Jacobson K., Mouritsen O.G., Anderson R.G. Lipid rafts: at a crossroad between cell biology and physics. Nat Cell Biol 2007, 9:7-14.
52. Hemler M.E. Integrin associated proteins. Curr Opin Cell Biol 1998, 10:578-585.
53. Zucchetto A., Vaisitti T., Benedetti D., et al. The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. Leukemia 2012, 26:1301-1312.
54. Bertagnolo V., Brugnoli F., Mischiati C., et al. Vav promotes differentiation of human tumoral myeloid precursors. Exp Cell Res 2005, 306:56-63.
55. Bustelo X.R. Vav proteins, adaptors and cell signaling. Oncogene 2001, 20:6372-6381.
56. Nobes C.D., Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 1995, 81:53-62.
57. Vigorito E., Gambardella L., Colucci F., McAdam S., Turner M. Vav proteins regulate peripheral B-cell survival. Blood 2005, 106:2391-2398.
58. de Rooij M.F., Kuil A., Geest C.R., et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012, 119:2590-2594.
59. Ponader S., Chen S.S., Buggy J.J., et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012, 119:1182-1189.
60. Quiroga M.P., Balakrishnan K., Kurtova A.V., et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009, 114:1029-1037.
61. Arroyo A.G., Yang J.T., Rayburn H., Hynes R.O. Alpha4 integrins regulate the proliferation/differentiation balance of multilineage hematopoietic progenitors in vivo. Immunity 1999, 11:555-566.
62. Miyake K., Weissman I.L., Greenberger J.S., Kincade P.W. Evidence for a role of the integrin VLA-4 in lympho-hemopoiesis. J Exp Med 1991, 173:599-607.
63. Koni P.A., Joshi S.K., Temann U.A., Olson D., Burkly L., Flavell R.A. Conditional vascular cell adhesion molecule 1 deletion in mice: impaired lymphocyte migration to bone marrow. J Exp Med 2001, 193:741-754.
64. Kunkel E.J., Butcher E.C. Chemokines and the tissue-specific migration of lymphocytes. Immunity 2002, 16:1-4.
65. Liu Y.J., Arpin C. Germinal center development. Immunol Rev 1997, 156:111-126.
66. Freedman A.S., Munro J.M., Rice G.E., et al. Adhesion of human B cells to germinal centers in vitro involves VLA-4 and INCAM-110. Science 1990, 249:1030-1033.
67. Kosco M.H., Pflugfelder E., Gray D. Follicular dendritic cell-dependent adhesion and proliferation of B cells in vitro. J Immunol 1992, 148:2331-2339.
68. Kurosaki T. Genetic analysis of B cell antigen receptor signaling. Annu Rev Immunol 1999, 17:555-592.
69. Kurosaki T. Regulation of B-cell signal transduction by adaptor proteins. Nat Rev Immunol 2002, 2:354-363.
70. Niiro H., Clark E.A. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2002, 2:945-956.
71. Spaargaren M., Beuling E.A., Rurup M.L., et al. The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J Exp Med 2003, 198:1539-1550.
72. Fiorcari S., Brown W.S., McIntyre B.W., et al. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS One 2013, 8:e83830.
73. Zucchetto A., Caldana C., Benedetti D., et al. CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. Blood 2013, 122:3317-3321.
74. Shanafelt T.D., Hanson C., Dewald G.W., et al. Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression. J Clin Oncol 2008, 26:e5-e6.
75. Liso V., Capalbo S., Lapietra A., Pavone V., Guarini A., Specchia G. Evaluation of trisomy 12 by fluorescence in situ hybridization in peripheral blood, bone marrow and lymph nodes of patients with B-cell chronic lymphocytic leukemia. Haematologica 1999, 84:212-217.
76. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010, 10:9-22.
77. de la Fuente M.T., Casanova B., Garcia-Gila M., Silva A., Garcia-Pardo A. Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia 1999, 13:266-274.
78. de la Fuente M.T., Casanova B., Cantero E., et al. Involvement of p53 in alpha4beta1 integrin-mediated resistance of B-CLL cells to fludarabine. Biochem Biophys Res Commun 2003, 311:708-712.
79. Buchner M., Baer C., Prinz G., et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 2010, 115:4497-4506.
80. Baudot A.D., Jeandel P.Y., Mouska X., et al. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression. Oncogene 2009, 28:3261-3273.
81. Longo P.G., Laurenti L., Gobessi S., Sica S., Leone G., Efremov D.G. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008, 111:846-855.
82. Matsusaka S., Tohyama Y., He J., et al. Protein-tyrosine kinase, Syk, is required for CXCL12-induced polarization of B cells. Biochem Biophys Res Commun 2005, 328:1163-1169.
83. Petlickovski A., Laurenti L., Li X., et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood 2005, 105:4820-4827.
84. Buggins A.G., Pepper C., Patten P.E., et al. Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. Cancer Res 2010, 70:7523-7533.
85. Hertlein E., Byrd J.C. Signalling to drug resistance in CLL. Best Pract Res Clin Haematol 2010, 23:121-131.
86. Brachtl G., Sahakyan K., Denk U., et al. Differential bone marrow homing capacity of VLA-4 and CD38 high expressing chronic lymphocytic leukemia cells. PLoS One 2011, 6:e23758.
87. Coscia M., Pantaleoni F., Riganti C., et al. IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia 2011, 25:828-837.
88. Rossi F.M., Zucchetto A., Tissino E., et al. CD49d expression identifies a chronic-lymphocytic leukemia subset with high levels of mobilized circulating CD34 hemopoietic progenitors cells. Leukemia 2014, 28:705-708.
89. Calissano C., Damle R.N., Marsilio S., et al. Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells. Mol Med 2011, 17:1374-1382.
90. Bomben R., Dal B.M., Capello D., et al. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. Br J Haematol 2009, 144:492-506.
91. Messmer B.T., Raphael B.J., Aerni S.J., et al. Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. Leuk Res 2009, 33:368-376.
92. Murray F., Darzentas N., Hadzidimitriou A., et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 2008, 111:1524-1533.
93. Stamatopoulos K., Belessi C., Moreno C., et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007, 109:259-270.
94. Rossi D., Spina V., Bomben R., et al. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. Blood 2013, 121:4902-4905.
95. Strefford J.C., Sutton L.A., Baliakas P., et al. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. Leukemia 2013, 27:2196-2199.